en · de · es · fr · pt
melanotan-2-notes.peptides4800.com › Wiki › Melanotan-2 Structure And Receptor Pharmacology — Reference Sheet

Melanotan-2 Structure And Receptor Pharmacology — Reference Sheet

By Editorial Desk · published 2025-11-19 · last reviewed 2025-12-10 · Wiki

A practical reference on melanocortin receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2025-12-10. Anything still debated is marked as such rather than presented as settled.

Melanotan-2 Structure and Receptor Pharmacology

Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.

No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.

Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.

Identity and Chemical Background

Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.

The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.

Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.

Melanotan-2 at a glance

PropertyValueNotes
Molecular formulaC50H69N15O9Free base; salt forms add to total mass
Molecular massAbout 1024 daltonsCalculated for the free base
Structural classCyclic heptapeptideContains D-phenylalanine and norleucine
Parent hormoneAlpha-melanocyte-stimulating hormoneEndogenous tridecapeptide of 13 residues
Receptor profileNon-selective melanocortin agonistInteracts with MC1R, MC3R, MC4R and MC5R

Melanotan-2 Identity and Receptor Pharmacology

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.

Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.

Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.

Related pages on this site

Notes from published material

== History and background == GFS was designed by Michael C. Giddings (University of North Carolina, Chapel Hill) et al., and released in 2003. Giddings expanded the algorithms for GFS from earlier ideas. Two papers were published in 1993 explaining the techniques used to identify proteins in sequence databases. These methods determined the mass of peptides using mass spectrometry, and then used the mass to search protein databases to identify the proteins In 1999 a more complex program was released called Mascot that integrated three types of protein/database searches: peptide molecular weights, tandem mass spectrometry from one or more peptide, and combination mass data with amino acid sequence. The fallback with this widely used program is that it is unable to detect alternative splice sites that are not currently annotated, and it not usually able to find proteins that have not been annotated. Giddings built upon these sources to create GFS which would compare peptide mass data to entire genomes to identify the proteins. Giddings system is able to find new annotations of genes that have not been found, such as undocumented genes and undocumented alternative splice sites.

After six weeks of indecision, Mahathir was appointed deputy prime minister on 5 March 1976. Several political figures praised his appointment, recognizing his proven ability and experience. The appointment meant that Mahathir was the anointed successor to the prime ministership. In October, Mahathir was appointed to lead a cabinet committee to review the Petroleum Development Act. To address the growing drug problem, Mahathir launched a nationwide anti-drug campaign in 1978 and announced plans to build a large rehabilitation centre on Pisang Island, Johor. He later warned that if the issue was not addressed, drug abuse could lead to the destruction of the nation. Mahathir is regarded as having been a successful Minister of Education and then Minister of Trade and Industry (1978–81). In the latter post, he implemented a "heavy industries policy", establishing a HICOM, a government-controlled corporation, to invest in the long-term development of manufacturing sectors such as an indigenous car industry. He spent much of his time in the ministry promoting Malaysia through overseas visits. Besides this, as UMNO deputy president, he played a key role in coordinating among the ten component parties of the ruling Barisan Nasional coalition. In the 1978 general election, Mahathir served as BN's election director for the state of Perak. In September 1978, Mahathir launched the Central Unit of the Federal Industrial Development Authority, a streamlined "one-stop agency" aimed at simplifying the application process for licences, permits, and facilities.

Skin-patch testing may also be used to determine whether an individual will experience a hypersensitivity reaction to abacavir, although some patients susceptible to developing AHS may not react to the patch test. The development of suspected hypersensitivity reactions to abacavir requires immediate and permanent discontinuation of abacavir therapy in all patients, including patients who do not possess the HLA-B*5701 allele. On 1 March 2011, the FDA informed the public about an ongoing safety review of abacavir and a possible increased risk of heart attack associated with the drug. A meta-analysis of 26 studies conducted by the FDA, however, did not find any association between abacavir use and heart attack

Sources: en.wikipedia.org

Further detail

== Functions == PLP is involved in many aspects of macronutrient metabolism, neurotransmitter synthesis, histamine synthesis, hemoglobin synthesis and function, and gene expression. PLP generally serves as a coenzyme (cofactor) for many reactions including decarboxylation, transamination, racemization, elimination, replacement, and beta-group interconversion.

== Bibliography == Biko, Steve (1979). Steve Biko: Black Consciousness in South Africa; Biko's Last Public Statement and Political Testament. Random House. ISBN 978-0-394-72739-4. Biko, Steve (2002). I Write What I Like: Selected Writings. University of Chicago Press. ISBN 978-0-226-04897-0. Clarke, Anthony J.; Fiddes, Paul S., eds. (2005). Flickering Images: Theology and Film in Dialogue. Regent's Study Guides. Vol. 12. Macon, GA: Smyth & Helwys Publishing. ISBN 1-57312-458-3. Goodwin, June (1995). Heart of Whiteness: Afrikaners Face Black Rule In the New South Africa. Scribner. ISBN 978-0-684-81365-3. Harlan, Judith (2000). Mamphela Ramphele. The Feminist Press at CUNY. ISBN 978-1-55861-226-6. Juckes, Tim (1995). Opposition in South Africa: The Leadership of Z. K. Matthews, Nelson Mandela, and Stephen Biko. Praeger Publishers. ISBN 978-0-275-94811-5. Magaziner, Daniel (2010). The Law and the Prophets: Black Consciousness in South Africa, 1968–1977. Ohio University Press. ISBN 978-0-8214-1918-2. Malan, Rian (2000). My Traitor's Heart: A South African Exile Returns to Face His Country, His Tribe, and His Conscience. Grove Press. ISBN 978-0-8021-3684-8. Omand, Roger (1989). Steve Biko and Apartheid (People & Issues). Hamish Hamilton Limited. ISBN 978-0-241-12640-0. Paul, Samuel (2009). The Ubuntu God: Deconstructing a South African Narrative of Oppression. Pickwick Publications. ISBN 978-1-55635-510-3. Pityana, Barney (1992). Bounds of Possibility: The Legacy of Steve Biko & Black Consciousness. D. Philip. ISBN 978-1-85649-047-4. Price, Linda (1992).

This shocks Minerva, who states that it leads to a world the Combine are sieging. Minerva betrays the protagonist after he sabotages the Combine's defenses, activating an orbital laser and attempting to destroy the base as she declares him a "redeemed traitor". He survives, however, and Minerva becomes apologetic, later admitting she has grown "attached" to him. She explains that the portal, wherever it may lead, could mean the difference between life and death for billions of people, hence her desperation to destroy it. She urges him to escape as she recharges the satellite's laser, as the Combine have become aware of her location and she fears retribution. With the aid of Minerva and a stolen helicopter, the protagonist fights to the surface and escapes the island just as it is annihilated by a second orbital blast. Minerva's communications are unusual in that each is prefixed by a time/date stamp in International Date Format (ISO 8601), giving an explicit timescale to the plot. These timestamps extend to several written pieces on the series's website that give background to the story. From these and the in-game messages it is possible to construct a partial timeline of events covered in the Minerva series.

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan-2 approved for medical use?

No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.

How does melanotan-2 differ from melanotan-1?

Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.

What is the connection to alpha-MSH?

Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.

Is melanotan-2 a naturally occurring substance?

No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.

Network